163 related articles for article (PubMed ID: 17505110)
1. Crystal structure of CD59: implications for molecular recognition of the complement proteins C8 and C9 in the membrane-attack complex.
Huang Y; Fedarovich A; Tomlinson S; Davies C
Acta Crystallogr D Biol Crystallogr; 2007 Jun; 63(Pt 6):714-21. PubMed ID: 17505110
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.
Rollins SA; Zhao J; Ninomiya H; Sims PJ
J Immunol; 1991 Apr; 146(7):2345-51. PubMed ID: 1706395
[TBL] [Abstract][Full Text] [Related]
3. Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8.
Lehto T; Meri S
J Immunol; 1993 Nov; 151(9):4941-9. PubMed ID: 7691959
[TBL] [Abstract][Full Text] [Related]
4. Role of a disulfide-bonded peptide loop within human complement C9 in the species-selectivity of complement inhibitor CD59.
Husler T; Lockert DH; Sims PJ
Biochemistry; 1996 Mar; 35(10):3263-9. PubMed ID: 8605162
[TBL] [Abstract][Full Text] [Related]
5. Characterization of rabbit complement component C8. Functional evidence for the species-selective recognition of C8 alpha by homologous restriction factor (CD59).
White RV; Kaufman KM; Letson CS; Platteborze PL; Sodetz JM
J Immunol; 1994 Mar; 152(5):2501-8. PubMed ID: 7510745
[TBL] [Abstract][Full Text] [Related]
6. A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes by C5b-9.
Tomlinson S; Whitlow MB; Nussenzweig V
J Immunol; 1994 Feb; 152(4):1927-34. PubMed ID: 7509832
[TBL] [Abstract][Full Text] [Related]
7. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
Rollins SA; Sims PJ
J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
[TBL] [Abstract][Full Text] [Related]
8. Regulation of the membrane attack complex of complement. Evidence that C8 gamma is not the target of homologous restriction factors.
Davé SJ; Sodetz JM
J Immunol; 1990 Apr; 144(8):3087-90. PubMed ID: 2324496
[TBL] [Abstract][Full Text] [Related]
9. Mapping the regions of the complement inhibitor CD59 responsible for its species selective activity.
Yu J; Dong S; Rushmere NK; Morgan BP; Abagyan R; Tomlinson S
Biochemistry; 1997 Aug; 36(31):9423-8. PubMed ID: 9235986
[TBL] [Abstract][Full Text] [Related]
10. Chimeric and truncated forms of human complement protein C8 alpha reveal binding sites for C8 beta and C8 gamma within the membrane attack complex/perforin region.
Plumb ME; Scibek JJ; Barber TD; Dunlap RJ; Platteborze PL; Sodetz JM
Biochemistry; 1999 Jun; 38(26):8478-84. PubMed ID: 10387094
[TBL] [Abstract][Full Text] [Related]
11. Binding of human and rat CD59 to the terminal complement complexes.
Lehto T; Morgan BP; Meri S
Immunology; 1997 Jan; 90(1):121-8. PubMed ID: 9038722
[TBL] [Abstract][Full Text] [Related]
12. Structure of human C8 protein provides mechanistic insight into membrane pore formation by complement.
Lovelace LL; Cooper CL; Sodetz JM; Lebioda L
J Biol Chem; 2011 May; 286(20):17585-92. PubMed ID: 21454577
[TBL] [Abstract][Full Text] [Related]
13. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9.
Tschopp J; Chonn A; Hertig S; French LE
J Immunol; 1993 Aug; 151(4):2159-65. PubMed ID: 8345200
[TBL] [Abstract][Full Text] [Related]
14. Chimeric horse/human recombinant C9 proteins identify the amino acid sequence in horse C9 responsible for restriction of hemolysis.
Tomlinson S; Wang Y; Ueda E; Esser AF
J Immunol; 1995 Jul; 155(1):436-44. PubMed ID: 7541424
[TBL] [Abstract][Full Text] [Related]
15. Transmembrane channel-formation by five complement proteins.
Müller-Eberhard HJ
Biochem Soc Symp; 1985; 50():235-46. PubMed ID: 2428370
[TBL] [Abstract][Full Text] [Related]
16. Identity of the segment of human complement C8 recognized by complement regulatory protein CD59.
Lockert DH; Kaufman KM; Chang CP; Hüsler T; Sodetz JM; Sims PJ
J Biol Chem; 1995 Aug; 270(34):19723-8. PubMed ID: 7544344
[TBL] [Abstract][Full Text] [Related]
17. The human complement regulatory protein CD59 binds to the alpha-chain of C8 and to the "b"domain of C9.
Ninomiya H; Sims PJ
J Biol Chem; 1992 Jul; 267(19):13675-80. PubMed ID: 1377690
[TBL] [Abstract][Full Text] [Related]
18. On the cause and nature of C9-related heterogeneity of terminal complement complexes generated on target erythrocytes through the action of whole serum.
Bhakdi S; Tranum-Jensen J
J Immunol; 1984 Sep; 133(3):1453-63. PubMed ID: 6747293
[TBL] [Abstract][Full Text] [Related]
19. High-resolution structures of bacterially expressed soluble human CD59.
Leath KJ; Johnson S; Roversi P; Hughes TR; Smith RA; Mackenzie L; Morgan BP; Lea SM
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2007 Aug; 63(Pt 8):648-52. PubMed ID: 17671359
[TBL] [Abstract][Full Text] [Related]
20. Identity of a peptide domain of human C9 that is bound by the cell-surface complement inhibitor, CD59.
Chang CP; Hüsler T; Zhao J; Wiedmer T; Sims PJ
J Biol Chem; 1994 Oct; 269(42):26424-30. PubMed ID: 7523406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
